What is Cyted Health?
Based in Cambridge, England, Cyted Health is a biotechnology firm dedicated to advancing treatments and understanding within the field of gastrointestinal diseases. The company's work is critical in an area of healthcare that affects a substantial portion of the global population, positioning it as a key player in the development of novel therapeutic solutions and diagnostic tools.
How much funding has Cyted Health raised?
Cyted Health has raised a total of $43.5M across 1 funding round:
Series B
$43.5M
Series B (2025): $43.5M with participation from BGF, EQT, Advent Life Sciences, The Morningside Group, and British Business Bank
Key Investors in Cyted Health
BGF
BGF is a highly active investor focused on supporting UK-based small and mid-sized businesses across various growth stages and sectors.
EQT
EQT Group is a global investment organization with diverse strategies including venture capital and growth equity, focusing on high-quality companies in sectors like healthcare and technology.
Advent Life Sciences
Advent Life Sciences is a venture capital firm specializing in early and mid-stage investments in innovative life sciences companies, aiming to bring new medicines and medical products to market.
What's next for Cyted Health?
The recent major strategic investment signifies a pivotal moment for Cyted Health, likely enabling the company to accelerate its research and development pipelines, expand its clinical trial operations, and potentially scale its commercialization efforts. This capital infusion is expected to fuel further innovation and solidify its market position in the competitive biotechnology landscape, particularly in addressing unmet needs in gastrointestinal health.
See full Cyted Health company page
